The role of “spillover” in antibiotic resistance

Short title: Antibiotic resistance “spillover”

Scott W. Olesen¹, Marc Lipsitch^{1,2}, Yonatan H. Grad^{1,3}

1 Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115

2 Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115

3 Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

Correspondence:

Yonatan Grad

Harvard T. H. Chan School of Public Health

665 Huntington Ave, Building 1, Room 715, Boston, Massachusetts 02115

617 432 2275

ygrad@hsph.harvard.edu

ABSTRACT (240 words)

Antibiotic use is a key driver of antibiotic resistance. Understanding the quantitative association between antibiotic use and resulting resistance is important for predicting future rates of antibiotic resistance and for designing antibiotic stewardship policy. However, the use-resistance association is complicated by “spillover”, in which one population’s level of antibiotic use affects another population’s level of resistance via the transmission of bacteria between those populations. Spillover is known to have effects at the level of families and hospitals, but it is unclear if spillover is relevant at larger scales. We used mathematical modeling and analysis of observational data to address this question. First, we used dynamical models of antibiotic resistance to predict the effects of spillover. Whereas populations completely isolated from one another do not experience any spillover, we found that if even 1% of interactions are between populations, then spillover may have large consequences: the effect of a change in antibiotic use in one population on antibiotic resistance in that population could be reduced by as much as 50%. Then, we quantified spillover in observational antibiotic use and resistance data from US states and European countries for 3 pathogen-antibiotic combinations, finding that increased interactions between populations were associated with smaller differences in antibiotic resistance between those populations. Thus, spillover may have an important impact at the level of states and countries, which has ramifications for predicting the future of antibiotic resistance, designing antibiotic resistance stewardship policy, and interpreting stewardship interventions.

INTRODUCTION

Antibiotic resistance is a major threat to public health (1). Outpatient antibiotic use, which accounts for approximately 80% of human antibiotic use (2,3), is considered a principal driver of antibiotic resistance in the community (4). Understanding the relationship between use and resistance is important because it allows accurate predictions of the future of antibiotic resistance and goal-oriented antibiotic stewardship policy. The use-resistance association has been previously characterized in many ecological studies at the level of US states (5–7) and European countries (8,9). However, antibiotic resistance is a complex, temporally dynamic phenomenon (10–13), and many factors complicate the use-resistance association, making what should be an “obvious” connection sometimes difficult to identify and quantify (11). Even when detected, observed use-resistance associations are sometimes weaker than might be expected (14). One factor that could account for the difficulty in detecting use-resistance associations in ecological studies and for the apparent weakness of such associations is “spillover”.

“Spillover” is a consequence of the fact that antibiotic-resistant and -susceptible bacteria can be transmitted from person to person. Thus, one person’s risk of an antibiotic resistant infection depends on their own antibiotic use (15,16) as well as the rates of antibiotic use among their contacts (17). For example, one person’s use of antibiotics increases the risk of an antibiotic resistant infection among their family members (18–21). As another example, hospitalized patients with no recent antibiotic use can have a higher risk of resistance than people in the community with high antibiotic use (22)

because antibiotic use and resistance in other hospitalized patients are high.

Spillover is important for three reasons. First, it means antibiotic resistance is not merely a localized problem. It is well-understood that new resistance determinants can emerge in one geography and spread globally (23,24), but the role of spillover in determining the levels of resistance in a given locale is not well-quantified. To what degree, for example, can one US state expect that its antibiotic resistance levels are due to antibiotic use within its borders, rather than in surrounding states? Second, spillover makes it difficult to design antibiotic stewardship interventions and understand their results. For example, if antibiotic use in one hospital changes, resistance might not change as expected because of spillover, from the community or other hospitals into that hospital's patients. Finally, spillover makes it difficult to interpret the results of controlled antibiotic interventions, such as the effect of mass drug administration on antibiotic resistance (25,26), when the intervention and control populations are not wholly epidemiologically separate.

The effect of spillover should scale with the amount of interaction between populations. If two populations do not interact at all, then antibiotic use in one population cannot affect resistance in the other. However, if two populations liberally exchange bacteria, then the rates of antibiotic resistance in the two populations will be very similar, regardless of whether their rates of antibiotic use differ greatly.

The effects of spillover also depend on population sizes. For example, two large

populations will have most interactions within themselves, rather than between each other. Spillover should therefore be most pronounced when considering small populations and become less important for large populations. As mentioned above, a single individual's risk of resistance is modulated by antibiotic use in their family or in their healthcare facility. Spillover is also observed at the level of hospitals, as the level of resistance in one hospital appears to be affected by resistance levels in nearby hospitals as well as by antibiotic use rates in the surrounding communities (27–29). Presumably, when examining ever larger populations, such as US Census tracts (30), US states, or European countries, the effect of spillover will become less important. However, the relationship between population size and spillover effects is not well understood.

We hypothesized that US states and European countries, which are large populations with relatively independent public health policies, may be subject to substantially lower levels of antibiotic resistance spillover than family- or hospital-sized populations. This hypothesis, if true, would mean that individual states or countries could act as independent “laboratories” of antibiotic use and resistance. If not, it means that outpatient antibiotic resistance policy must be national or international in order to achieve its full effect. To evaluate this hypothesis, we first use mathematical models of antibiotic use and resistance to make quantitative predictions about the effect of spillover between populations as a function of their amount of mutual interaction. Then, we search for signals of spillover in observational data of antibiotic use and resistance in US states and European countries.

METHODS

Dynamical model of antibiotic resistance

To examine how interactions between populations could theoretically affect the association between antibiotic use and resistance, we used the within-host neutrality (WHN) mathematical model presented by Davies *et al.* (31) and described in the Supplemental Methods. Briefly, the model predicts the prevalence ρ of antibiotic resistance that results from an antibiotic use rate r in a single, well-mixed population. To verify that conclusions drawn from the WHN model are not specific to the model structure, we also repeated all analyses with the “D-types” model of use and resistance (32). We selected these two models because they demonstrate coexistence between sensitive and resistant strains at equilibrium over a wide parameter space. Parameter values and simulation methodology for both models are in the Supplemental Methods. In the simulations, antibiotic use is measured as monthly treatments per capita and resistance as the proportion of colonized hosts carrying resistant strains.

To conceptually frame and clarify the question of spillover, we simulated an antibiotic stewardship intervention experiment using a structured host population approach inspired by Blanquart *et al.* (33). We considered pairs of an intervention population with antibiotic use rate r_{int} and a control population with use rate r_{cont} . To determine how spillover affects the intervention’s measured outcome, we modulated the proportion ε of each population’s contacts that are in the other population. For $\varepsilon = 0\%$, the populations

are completely separate. For $\varepsilon = 50\%$, contacts across populations are just as likely as contacts within populations (Supplemental Methods). We varied ε between 0% and 50%, and we varied the difference in use $\Delta\tau = \tau_{\text{cont}} - \tau_{\text{int}}$ between 0 and 0.15 treatments per person per month while keeping the average use $0.5 \times (\tau_{\text{cont}} + \tau_{\text{int}})$ fixed at 0.125, reflecting the range of antibiotic use rates in the original model presentations.

Observational data

We examined antibiotic use and resistance for 3 pathogen-antibiotic combinations: *S. pneumoniae* and macrolides, *S. pneumoniae* and β -lactams, and *Escherichia coli* and quinolones. We considered these 3 combinations because they are the subject of many modeling (31,32) and empirical studies (5,15).

Observational data were drawn from 3 sources. First, we used MarketScan (34) and ResistanceOpen (35) as previously described (7). The MarketScan data includes outpatient pharmacy antibiotic prescription claims for 62 million unique people during 2011-2014. ResistanceOpen includes antibiotic resistance data collected during 2012-2015 from 230 hospitals, laboratories, and surveillance units in 44 states. Second, we used the QuintilesIMS Xponent database (36) and the US Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network (NHSN) (37). The Xponent data includes state-level data on US quinolone use during 2011-2014. NHSN includes state-level data on quinolone resistance among *E. coli* catheter-associated urinary tract infections during 2011-2014. Third, we used the European Center for Disease Prevention and Control's (ECDC) ESAC-Net antimicrobial consumption database (38)

and EARS-Net Surveillance Atlas of Infectious Disease (39) for 2011-2015. The ESAC-Net data includes country-level outpatient antibiotic use data provided by WHO and Ministries of Health from member countries. The EARS-Net data includes country-level resistance data. In the observational data, we quantified antibiotic use as yearly treatments per capita and resistance as the proportion of collected isolates that were non-susceptible. Further details about preparation of these data sources and their availability are in the Supplemental Methods.

We excluded the *S. pneumoniae* resistance to β -lactams in US states from the analysis because, in previous work using the same primary datasets, the point estimate for the use-resistance relationship was negative (14).

Use-resistance relationships by populations' adjacency

To test the theoretical prediction that the same difference in antibiotic use will be associated with smaller differences in antibiotic resistance when two populations (US states or European countries) have stronger interactions, we tested whether the use-resistance association is weaker in adjacent pairs of populations, which presumably have more cross-population contacts, compared to non-adjacent populations. Two populations were considered adjacent if they share a land or river border (40–42).

We quantified the use-resistance association as the percentage point difference (i.e., absolute risk difference) in resistance (proportion of non-susceptible isolates) divided by the difference in antibiotic use. We summarized use-resistance associations among

adjacent pairs and non-adjacent pairs of populations using the median value. Because use-resistance associations between pairs of populations are correlated, we used the jackknife method to compute confidence intervals on the difference in medians between groups. We used the Mann-Whitney U test to compute statistical significance. Because our theoretical results suggested the ratio of percentage points difference in resistance divided by difference in antibiotic use rates was a predictable function of the degree of population mixing, we considered only this functional form for the use-resistance association.

Use-resistance associations by interactions

Because adjacency might be too coarse measure of populations' interactions to detect spillover, we performed a similar analysis as above, but predicting the use-resistance association between populations using transportation data. For US states, we used inter-county commuting statistics from the US Census (43). For European countries, we used inter-country passenger flight data from Eurostat (44). Rather than trying to infer a precise mathematical relationship between transportation statistics and epidemiological contacts, we used a nonparametric approach: we assumed that pairs of populations with relatively little inter-population transportation also have relatively few inter-population contacts, but we infer only the rank ordering of inter-population contacts, not their magnitudes. Specifically, we first converted the matrix of the number of counts (workers in the commuting data and passengers in the flight data) from each population to every other population into the proportion of counts moving from one population to another (i.e., divided each row by its sum), then symmetrized the resulting matrix (taking

the elementwise average of the matrix and its transpose), and finally converted the resulting values into ranks. We assumed that intra-population interactions outnumber inter-population interactions and so set diagonal entries, which represent within-population interactions, to the highest rank. We measured the association between ranked interactions and use-resistance associations using the nonparametric Spearman's correlation, computed confidence intervals using the jackknife method, and tested for statistical significance using the Mantel test with 999 permutations. To quantify the effect of spillover, we compared the median use-resistance associations among the top and bottom decile of ranked interactions.

Simulations and observational analyses were made using R (version 3.6.0) (45). The Mantel test used the *vegan* package (46). Multiple hypotheses were accounted for using Benjamini-Hochberg false discovery rate.

RESULTS

In simulations of two populations, representing an intervention and control group, interactions between the two populations attenuated the effect of the intervention (Figure 1). With increasing interaction strength, the same intervention, that is, the same difference in antibiotic use between the populations, was associated with a smaller difference in antibiotic resistance. The difference in resistance between populations increases with the difference in antibiotic use (Figure 1d), but the use-resistance association, measured as the ratio of the difference in resistance to the difference in

use, depends strongly on the interaction strength (Figure 1e). Thus, spillover between populations attenuates the measured use-resistance association.

The precise relationship between ϵ , the proportion of each population's contacts that are in the other population, and the attenuation of the use-resistance association depended on the choice of mathematical model (Supplemental Table 1, Supplemental Figure 1). For $\epsilon = 1\%$, the use-resistance declined by approximately 30% in the WHN model and more than 60% in the "D-types" model. In other words, the models predict that as few as 1% of contacts need to be across populations, rather than within populations, to cause the observed effect of an antibiotic stewardship intervention to shrink by one-third, or even half.

To test whether spillover is important at the scale of US states or European countries, we measured use-resistance associations between pairs of populations in 6 combinations of pathogen species, antibiotic class, and data source (Figure 2). We reasoned that if spillover is relevant at these scales, then pairs of states or countries with stronger interactions would have detectably weaker use-resistance associations.

We first tested whether pairs of physically adjacent populations (e.g., Massachusetts and Connecticut) had weaker use-resistance associations than non-adjacent populations (e.g., Massachusetts and Alaska). In 5 of 6 pathogen/antibiotic/dataset combinations, the median use-resistance association was smaller among adjacent populations than among non-adjacent populations (Figure 3), but in no case was the

difference statistically significant after multiple hypothesis correction (Supplemental Table 2). Point estimates of the relative difference in median use-resistance associations between adjacent populations were 18% to 50% weaker than between non-adjacent populations (excepting *S. pneumoniae* with β -lactams, which was an outlier), consistent with the theoretical modeling results showing a 50% reduction in the use-resistance association for populations with approximately 1% of interactions across populations (Supplemental Table 1).

Next, to account for the possibility that adjacency was too coarse a measure for interactions between populations, we instead used a rank-ordered estimate of interactions using US commuting and European airline passenger flows (Supplemental Figure 2). In 4 of 6 dataset/pathogen/antibiotic combinations, the nonparametric association between increased inter-population interactions and decreased use-resistance associations was statistically significant, thus confirming the general trend observed in the adjacency analysis (Figure 4, Supplemental Table 3). The weakest significant result was for *S. pneumoniae* and macrolides in the MarketScan/ResistanceOpen dataset (Spearman's ρ 0.07, 95% jackknife confidence interval -0.03 to 0.18; $p = 0.028$, Mantel test), and the strongest was for *E. coli* and quinolones in the Xponent/NHSN dataset ($\rho = 0.13$, 95% jackknife confidence interval 0.007 to 0.25; $p = 0.001$). The correlation for *S. pneumoniae* and macrolides in the ECDC data has a point estimate suggesting spillover but was not statistically significant, while the correlation for *S. pneumoniae* and β -lactams in the ECDC data had the opposite point estimate, consistent with the adjacency analysis (Figure 3).

Finally, to quantify the effect of increased interactions on the observed use-resistance associations, we compared the use-resistance associations in pairs of populations within the lowest decile of interactions against those in the highest decile, using the same approach as for the adjacency analysis above (Supplemental Table 4). In 5 of 6 dataset/pathogen/antibiotic combinations, the point estimate for the different in use-resistance associations was consistent with spillover, with a weaker association among pairs of populations with greater interactions. In those 5 cases, the point estimates ranged from a 18% reduction up to a 75% reduction in use-resistance associations among the highest-interacting pairs of populations, compared to the lowest-interacting populations.

DISCUSSION

We used theoretical models to show that interactions between two populations can attenuate the observed use-resistance association. In simulations, the quantitative relationship between inter-population interactions and the attenuation of the use-resistance association was dependent on the theoretical model used. However, we found that, in two models of the use-resistance association, having on the order of 1% of interactions between a control and intervention population was sufficient to attenuate the observed effect of theoretical stewardship intervention by 50%, relative to a situation where the two populations were completely isolated. These theoretical results suggest that even small numbers of interactions could lead to substantial spillover.

276

277 When examining observational antibiotic use and resistance data from US states and

278 European countries, we did not detect a robust signal of spillover among pairs of

279 adjacent populations, as opposed to non-adjacent pairs, even across 3 pathogen-

280 antibiotic combinations in 3 separate datasets. However, when using more fine-grained

281 transportation data to estimate the relative ranking of epidemiological contacts between

282 those populations, we found a correlation between increased interactions and

283 attenuated use-resistance associations. Pairs of populations in the highest decile of

284 inter-population interactions, that is, those most subject to spillover, had use-resistance

285 associations on the order of 50% weaker than pairs in the lowest decile of interactions.

286 The 2 pathogen/antibiotic dataset combinations with data not indicative of spillover,

287 namely *S. pneumoniae* and β -lactams and macrolides in the ECDC data, may have not

288 shown the same signal as other cases because of the smaller number of populations in

289 those cases (27, versus 28 to 50 in the other cases) led to insufficient statistical power

290 or potentially because the biology or epidemiology of *S. pneumoniae* resistance in these

291 cases is somehow different and does not exhibit spillover.

292

293 These theoretical and empirical results suggest that spillover is relevant at the level of

294 US states and European countries. This finding has important ramifications. First,

295 attempts to attribute changes in a population's level of antibiotic resistance to changes

296 in that population's rates of antibiotic use may lead to inaccurate conclusions unless use

297 and resistance in surrounding populations is accounted for. Second, state- or country-

298 level antibiotic stewardship pilot studies may substantially underestimate the potential

reduction in antibiotic resistance that would follow from a reduction in antibiotic use if that reduction were implemented at a larger scale. Third, mass drug administration trials may lead to elevated levels of antibiotic resistance in the control populations if those populations are not entirely separated from the intervention population. Finally, spillover can at least partly explain why use-resistance associations at the level of US states or European countries are sometimes difficult to detect and, when they are detected, are sometimes weaker than expected (5,11,14). Furthermore, spillover means that theoretical models of antibiotic use and resistance that treat US states or European countries as epidemiologically independent populations will not accurately represent the dynamics of resistance (33).

Our study has several limitations. First, we interpreted the theoretical results and ecological data as if the association between antibiotic use and resistance were causal and deterministic. However, decreases in the use of an antibiotic may not necessarily lead to declines in resistance to that antibiotic in a target pathogen (12,47–49). We do not address co-resistance and cross-selection (50,51), and we assumed that resistance equilibrates on a timescale comparable to an intervention. Previous research has shown that resistance among *E. coli*, *S. pneumoniae*, *N. gonorrhoeae* and other organisms can respond to changes in antibiotic use on the timescale of months (52–55), but the expected delay between a perturbation to antibiotic use and the resulting change in resistance remains a subject of active study (13,52,56,57). Nevertheless, the use of ecological data was essential to addressing our hypothesis, as data from multiple controlled, state- or country-wide experiments are not available.

Second, our analyses attributed all differences in antibiotic resistance between populations to differences in use across those populations and to interactions between them. In fact, antibiotic resistance is associated with factors beyond antibiotic use (6,58), and those factor are likely spatially correlated. In other words, closely interacting populations might have more similar use-resistance associations because they tend to be more similar with respect to other determinants of antibiotic use. Our estimates of the correlation between inter-population interactions and the attenuation of use-resistance relationships may therefore be overestimates. A more careful quantification of the relative roles of spillover versus other spatially-correlated determinants of resistance is required.

Third, our analysis only considered pairs of populations, when in fact spillover is happening between all pairs of populations in our analysis simultaneously. We used the pairs approach because it allowed for a simple theoretical model and a straightforward comparison of theory with the observational data. However, more sophisticated approaches that account for the network of spillover interactions will likely lead to more refined characterizations of spillover.

Finally, analyses based on administrative entities like US states or European countries, although logistically attractive “laboratories” of antibiotic stewardship, will always be difficult to interpret because administrative entities average over important dimensions of population structure like age (59), sexual networks (60), and race/ethnicity (61). Thus,

use-resistance associations measured across states and countries may be different from those that appear among geographically-proximate populations with dissimilar antibiotic use rates, such as the sexes (62) and racial/ethnic groups (63).

We suggest 3 lines of investigation that could refine our understanding about the role of spillover at levels of US states and European countries. First, further mathematical modeling studies with more realistic structuring of the host population might articulate more detailed theoretical expectations about the relationship between intervention scale and spillover. For example, models could be parameterized with epidemiological information about individuals' contacts and travel patterns, as has been done for other infectious diseases (64). Second, meta-analysis of existing studies of use-resistance relationships (5,65,66), both experimental and observational, could potentially determine the empirical relationship between intervention population size and the importance of spillover. This kind of meta-analysis might reveal that populations other than US states are feasible "laboratories" for resistance: it may be that cities, daycares, schools, workplaces, or even families represent the optimal trade-off between maximizing logistical feasibility and minimizing spillover. Finally, future experimental outpatient antibiotic stewardship interventions should make careful and deliberate decisions about the sizes and interconnectedness of the populations they target. We hope that a better understanding of spillover will improve predictions about the future of antibiotic resistance, the formulation of stewardship policy, the design of stewardship interventions and antibiotic administration trials, and theoretical models of resistance.

References

1. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. 2016.
2. Public Health England. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR). 2014.
3. Public Health Agency of Sweden, National Veterinary Institute. Consumption of antibiotics and occurrence of antibiotic resistance in Sweden.
4. US Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. 2013.
5. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infect Dis*. 2014 Jan 9;14:13.
6. MacFadden DR, McGough SF, Fisman D, Santillana M, Brownstein JS. Antibiotic resistance increases with local temperature. *Nat Clim Change*. 2018 Jun;8(6):510–4.
7. Olesen SW, Barnett ML, MacFadden DR, Brownstein JS, Hernández-Díaz S, Lipsitch M, et al. The distribution of antibiotic use and its association with antibiotic resistance. *eLife* [Internet]. 2018 Dec 18 [cited 2018 Dec 19];7. Available from: <https://elifesciences.org/articles/39435>
8. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet*. 2005 Feb 12;365(9459):579–87.
9. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. *Emerg Infect Dis*. 2008 Nov;14(11):1722–30.
10. Livermore DM. The 2018 Garrod Lecture: Preparing for the Black Swans of resistance. *J Antimicrob Chemother*. 2018 Nov 1;73(11):2907–15.
11. Turnidge J, Christiansen K. Antibiotic use and resistance--proving the obvious. *Lancet Lond Engl*. 2005 Feb;365(9459):548–9.
12. Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. Clonal Spread of Resistant Pneumococci Despite Diminished Antimicrobial Use. *Microb Drug Resist*. 2002 Sep;8(3):187–92.
13. Lipsitch M. The rise and fall of antimicrobial resistance. *Trends Microbiol*. 2001 Sep;9(9):438–44.

14. Olesen SW, Barnett ML, MacFadden DR, Brownstein JS, Hernández-Díaz S, Lipsitch M, et al. The distribution of antibiotic use and its association with antibiotic resistance. *eLife* [Internet]. 2018 Dec 18 [cited 2019 Sep 23];7. Available from: <https://elifesciences.org/articles/39435>
15. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ*. 2010 May 18;340:c2096.
16. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. *Clin Infect Dis*. 2001;33:1462–8.
17. Lipsitch M. Measuring and Interpreting Associations between Antibiotic Use and Penicillin Resistance in *Streptococcus pneumoniae*. *Clin Infect Dis*. 2001 Apr 1;32(7):1044–54.
18. Hannah EL, Angulo FJ, Johnson JR, Haddadin B, Williamson J, Samore MH. Drug-resistant *Escherichia coli*, Rural Idaho. *Emerg Infect Dis*. 2005 Oct;11(10):1614–7.
19. Kalter HD, Gilman RH, Moulton LH, Cullotta AR, Cabrera L, Velapatiño B. Risk factors for antibiotic-resistant *Escherichia coli* carriage in young children in Peru: community-based cross-sectional prevalence study. *Am J Trop Med Hyg*. 2010 May;82(5):879–88.
20. Samore MH, Magill MK, Alder SC, Severina E, Morrison-De Boer L, Lyon JL, et al. High rates of multiple antibiotic resistance in *Streptococcus pneumoniae* from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. *Pediatrics*. 2001 Oct;108(4):856–65.
21. Gottesman B-S, Low M, Almog R, Chowers M. Quinolone Consumption by Mothers Increases Their Children's Risk of Acquiring Quinolone-Resistant Bacteriuria. *Clin Infect Dis* [Internet]. 2019 Aug 29 [cited 2019 Dec 2]; Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz858/5556473>
22. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. *Emerg Infect Dis*. 2002;8:347–54.
23. Moellering RC. NDM-1 — A Cause for Worldwide Concern. *N Engl J Med*. 2010 Dec 16;363(25):2377–9.
24. Wang R, van Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, et al. The global distribution and spread of the mobilized colistin resistance gene *mcr-1*. *Nat Commun* [Internet]. 2018 Dec [cited 2020 Jun 26];9(1). Available from: <http://www.nature.com/articles/s41467-018-03205-z>

25. Bogoch II, Utzinger J, Lo NC, Andrews JR. Antibacterial mass drug administration for child mortality reduction: Opportunities, concerns, and possible next steps. Bhutta ZA, editor. *PLoS Negl Trop Dis*. 2019 May 23;13(5):e0007315.
26. Doan T, Arzika AM, Hinterwirth A, Maliki R, Zhong L, Cummings S, et al. Macrolide Resistance in MORDOR I — A Cluster-Randomized Trial in Niger. *N Engl J Med*. 2019 Jun 6;380(23):2271–3.
27. Cooper BS, Medley GF, Stone SP, Kibbler CC, Cookson BD, Roberts JA, et al. Methicillin-resistant *Staphylococcus aureus* in hospitals and the community: Stealth dynamics and control catastrophes. *Proc Natl Acad Sci*. 2004 Jul 6;101(27):10223–8.
28. MacFadden DR, Fishman DN, Hanage WP, Lipsitch M. The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-Spectrum Beta-lactamase-Producing *Escherichia coli*. *Clin Infect Dis* [Internet]. 2018 [cited 2018 Nov 29]; Available from: <https://www.ncbi.nlm.nih.gov/pubmed/30462185>
29. Knight GM, Costelloe C, Deeny SR, Moore LSP, Hopkins S, Johnson AP, et al. Quantifying where human acquisition of antibiotic resistance occurs: a mathematical modelling study. *BMC Med*. 2018 23;16(1):137.
30. Klevens RM, Caten E, Olesen SW, DeMaria A, Troppy S, Grad YH. Outpatient Antibiotic Prescribing in Massachusetts, 2011–2015. *Open Forum Infect Dis* [Internet]. 2019 May 1 [cited 2019 Sep 15];6(5). Available from: <https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofz169/5430941>
31. Davies NG, Flasche S, Jit M, Atkins KE. Within-host dynamics shape antibiotic resistance in commensal bacteria. *Nat Ecol Evol*. 2019 Mar;3(3):440–9.
32. Lehtinen S, Blanquart F, Croucher NJ, Turner P, Lipsitch M, Fraser C. Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. *Proc Natl Acad Sci*. 2017 Jan 31;114(5):1075–80.
33. Blanquart F, Lehtinen S, Lipsitch M, Fraser C. The evolution of antibiotic resistance in a structured host population. *J R Soc Interface*. 2018 Jun;15(143).
34. Truven Health MarketScan Database. Commercial Claims and Encounters. Ann Arbor, MI; 2015.
35. MacFadden DR, Fisman D, Andre J, Ara Y, Majumder MS, Bogoch II, et al. A Platform for Monitoring Regional Antimicrobial Resistance, Using Online Data Sources: ResistanceOpen. *J Infect Dis*. 2016 Dec 1;214(suppl_4):S393–8.
36. US Centers for Disease Control and Prevention. Patient Safety Atlas - Outpatient Antibiotic Use [Internet]. [cited 2018 Oct 25]. Available from: <https://gis.cdc.gov/grasp/PSA/indexAU.html>

37. US Centers for Disease Control and Prevention. Patient Safety Atlas - Antibiotic Resistance [Internet]. [cited 2018 Oct 25]. Available from: <https://gis.cdc.gov/grasp/PSA/AboutTheData.html>
38. European Centre for Disease Prevention and Control. Antimicrobial consumption database [Internet]. European Centre for Disease Prevention and Control. [cited 2018 Oct 25]. Available from: <http://ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database>
39. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases [Internet]. [cited 2018 Oct 25]. Available from: <https://atlas.ecdc.europa.eu/public/index.aspx>
40. US Census. County Adjacency File [Internet]. Available from: <https://www.census.gov/geo/reference/county-adjacency.html>
41. Correlates of War Project. Direct Contiguity Data, 1816-2016 (v3.2) [Internet]. Available from: <http://correlatesofwar.org/data-sets/direct-contiguity>
42. Stinnett DM, Tir J, Diehl PF, Schafer P, Gochman C. The Correlates of War (Cow) Project Direct Contiguity Data, Version 3.0. *Confl Manag Peace Sci*. 2002 Sep;19(2):59–67.
43. US Census. 2011-2015 5-Year ACS Commuting Flows [Internet]. Available from: <https://www.census.gov/data/tables/2015/demo/metro-micro/commuting-flows-2015.html>
44. Eurostat. Air transport measurement [Internet]. Available from: https://ec.europa.eu/eurostat/cache/metadata/en/avia_pa_esms.htm
45. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna; 2018. Available from: www.R-project.org
46. Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, et al. *vegan*: Community Ecology Package. R package version 2.5-6.
47. Hennessy TW, Petersen KM, Bruden D, Parkinson AJ, Hurlburt D, Getty M, et al. Changes in Antibiotic-Prescribing Practices and Carriage of Penicillin-Resistant *Streptococcus pneumoniae*: A Controlled Intervention Trial in Rural Alaska. *Clin Infect Dis*. 2002 Jun 15;34(12):1543–50.
48. Sundqvist M, Geli P, Andersson DI, Sjölund-Karlsson M, Runeheggen A, Cars H, et al. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. *J Antimicrob Chemother*. 2010 Feb;65(2):350–60.
49. Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance in *Escherichia coli* in the UK despite national prescribing restriction. *Lancet Lond Engl*. 2001 Apr 28;357(9265):1325–8.

50. Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, et al. Association between use of different antibiotics and trimethoprimresistance: going beyond the obvious crude association. *J Antimicrob Chemoth.* 2018;
51. Tedijanto C, Olesen SW, Grad YH, Lipsitch M. Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. *Proc Natl Acad Sci.* 2018 Dec 18;115(51):E11988–95.
52. Olesen SW, Torrone EA, Papp JR, Kirkcaldy RD, Lipsitch M, Grad YH. Azithromycin Susceptibility Among *Neisseria gonorrhoeae* Isolates and Seasonal Macrolide Use. *J Infect Dis* [Internet]. 2018 [cited 2018 Nov 6]; Available from: <http://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiy551/5098400>
53. Dagan R, Barkai G, Givon-Lavi N, Sharf AZ, Vardy D, Cohen T, et al. Seasonality of Antibiotic-Resistant *Streptococcus pneumoniae* That Causes Acute Otitis Media: A Clue for an Antibiotic-Restriction Policy? *J Infect Dis.* 2008 Apr 15;197(8):1094–102.
54. Sun L, Klein EY, Laxminarayan R. Seasonality and Temporal Correlation between Community Antibiotic Use and Resistance in the United States. *Clin Infect Dis.* 2012 Sep 1;55(5):687–94.
55. Blanquart F, Lehtinen S, Fraser C. An evolutionary model to predict the frequency of antibiotic resistance under seasonal antibiotic use, and an application to *Streptococcus pneumoniae*. *Proc R Soc B.* 2017 May 31;284(1855):20170679.
56. Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, et al. Effects of control interventions on *Clostridium difficile* infection in England: an observational study. *Lancet Infect Dis.* 2017 Apr;17(4):411–21.
57. McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, et al. Geographic diversity and temporal trends of antimicrobial resistance in *Streptococcus pneumoniae* in the United States. *Nat Med.* 2003 Apr;9(4):424–30.
58. Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. *Lancet Planet Health.* 2018 Sep;2(9):e398–405.
59. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. *PLoS Med.* 2008 Mar 25;5(3):e74.
60. Garrett G, Hughes J, Anderson R, Stoner B, Aral S, Whittington W, et al. Sexual mixing patterns of patients attending sexually transmitted diseases clinics. *Sex Transm Dis.* 1996;23(3):248–57.

61. Newman MEJ. Mixing patterns in networks. *Phys Rev E Stat Nonlin Soft Matter Phys.* 2003 Feb;67(2 Pt 2):026126.
62. Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH, et al. US Outpatient Antibiotic Prescribing Variation According to Geography, Patient Population, and Provider Specialty in 2011. *Clin Infect Dis.* 2015 May 1;60(9):1308–16.
63. Olesen SW, Grad YH. Racial/Ethnic Disparities in Antimicrobial Drug Use, United States, 2014–2015. *Emerg Infect Dis* [Internet]. 2018 [cited 2018 Nov 6];24(11). Available from: https://wwwnc.cdc.gov/eid/article/24/11/18-0762_article
64. Charu V, Zeger S, Gog J, Bjørnstad ON, Kissler S, Simonsen L, et al. Human mobility and the spatial transmission of influenza in the United States. *PLoS Comput Biol.* 2017;13(2):e1005382.
65. Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ. Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. *Clin Microbiol Rev.* 2013 Apr;26(2):289–307.
66. O'Brien KS, Emerson P, Hooper P, Reingold AL, Dennis EG, Keenan JD, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. *Lancet Infect Dis* [Internet]. 2018 Oct 3 [cited 2018 Nov 7]; Available from: <http://www.sciencedirect.com/science/article/pii/S1473309918304444>

Disclaimers

The views and opinions of the authors expressed herein do not necessarily state or reflect those of the ECDC. The accuracy of the authors' statistical analysis and the findings they report are not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn from the data provided. ECDC is not responsible for the correctness of the data and for data management, data merging and data collation after provision of the data. ECDC shall not be held liable for improper or incorrect use of the data.

Funding

This work was supported by the National Institutes of Health (grant number U54GM088558 to ML). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank Dr. Stephen M. Kissler for helpful comments on the manuscript.

Figure 1. Interactions between populations attenuate the effect of interventions.
 (a) Schematic of the 2-population model. (b) Results of simulations of the 2-population WHN model for a modest intervention (difference in antibiotic use between populations $\Delta\tau = 0.05$ monthly treatments per capita; average of control and intervention treatment rates 0.125). As interaction strength (ε , horizontal axis) increases, the difference in antibiotic resistance between the two populations decreases. Dotted line shows resistance level in populations before the intervention. (c) The same pattern holds for a stronger intervention ($\Delta\tau = 0.1$, same average treatment rate). (d) In general, the difference in resistance between populations ($\Delta\rho$, vertical axis) increases with the difference in antibiotic use ($\Delta\tau$, horizontal axis). (e) However, in the WHN model, the use-resistance relationship ($\Delta\rho/\Delta\tau$, vertical axis) depends mostly on the interaction strength ε and is mostly independent of the difference in antibiotic use $\Delta\tau$.

Figure 2. Use-resistance relationships across US states and European countries.

Each point represents antibiotic use and resistance in a US state (top row) or European country (bottom row). Lines show simple linear regression best fit. Gray areas show 95% confidence interval. Ec/q: *E. coli* and quinolones. Sp/m: *S. pneumoniae* and macrolides. Sp/bl: *S. pneumoniae* and β -lactams. RO: ResistanceOpen. ECDC: European CDC.

Figure 3. Use-resistance relationships by adjacency. Each point represents the use-resistance association in populations (top row, US states; bottom row, European countries), the same as those shown in Figure 2, arranged by whether the pair of populations is physically adjacent. Physically adjacent populations tend to have weaker use-resistance associations, but differences were not statistically significant. For visual clarity, the vertical axes are truncated to show only the central 90% of data points. Ec/q: *E. coli* and quinolones. Sp/m: *S. pneumoniae* and macrolides. Sp/bl: *S. pneumoniae* and β -lactams. RO: ResistanceOpen. ECDC: European CDC.

Figure 4. Use-resistance associations by ranked interaction. Each point represents the use-resistance association in a pair of US states (top row) or European countries (bottom row), the same pairs as shown in Figure 3, rank ordered by increasing inter-population interaction as inferred from transportation data. For visual clarity, the horizontal axes are truncated to exclude outliers. The dashed red line is a visual illustration of how increasing interaction is correlated with decreasing use-resistance associations (robust regression; compare Supplemental Tables 3 and 4). The asterisk (*) indicates a statistically significant association between increased interaction and decreased use-resistance relationship (Supplemental Table 3). Ec/q: *E. coli* and quinolones. Sp/m: *S. pneumoniae* and macrolides. Sp/bl: *S. pneumoniae* and β -lactams. RO: ResistanceOpen. ECDC: European CDC.